CERT Stock - Certara, Inc.
Unlock GoAI Insights for CERT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $385.15M | $354.34M | $335.64M | $286.10M | $243.53M |
| Gross Profit | $230.63M | $213.31M | $203.07M | $174.49M | $142.76M |
| Gross Margin | 59.9% | 60.2% | 60.5% | 61.0% | 58.6% |
| Operating Income | $-1,731,000 | $-40,774,000 | $32.52M | $13.58M | $-24,420,000 |
| Net Income | $-12,051,000 | $-55,357,000 | $14.73M | $-13,266,000 | $-49,397,000 |
| Net Margin | -3.1% | -15.6% | 4.4% | -4.6% | -20.3% |
| EPS | $-0.08 | $-0.35 | $0.09 | $-0.09 | $-0.32 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 21st 2025 | Rothschild & Co Redburn | Initiation | Buy | $10 |
| November 13th 2025 | BMO Capital Markets | Initiation | Market Perform | $9 |
| September 29th 2025 | Craig Hallum | Initiation | Buy | $16 |
| July 3rd 2025 | Morgan Stanley | Resumed | Equal Weight | $16 |
| May 8th 2025 | Barclays | Upgrade | Overweight | $14 |
| February 27th 2025 | TD Cowen | Initiation | Buy | $16 |
| September 27th 2024 | UBS | Upgrade | Buy | $16 |
| April 10th 2024 | KeyBanc Capital Markets | Upgrade | Overweight | $23 |
| April 4th 2024 | JMP Securities | Initiation | Market Perform | - |
| February 26th 2024 | Leerink Partners | Initiation | Market Perform | $19 |
| December 7th 2023 | UBS | Initiation | Neutral | $17 |
| December 5th 2023 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| August 22nd 2023 | Jefferies | Downgrade | Hold | $17← $24.5 |
| August 10th 2023 | William Blair | Downgrade | Market Perform | - |
| April 12th 2023 | Stephens | Initiation | Overweight | $28 |
Earnings History & Surprises
CERTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | $0.12 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.11 | $0.14 | +27.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.10 | $0.07 | -30.0% | ✗ MISS |
Q2 2025 | May 5, 2025 | $0.13 | $0.14 | +7.7% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.13 | $0.15 | +15.4% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.11 | $0.13 | +18.2% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.11 | $0.07 | -36.4% | ✗ MISS |
Q2 2024 | May 7, 2024 | $0.10 | $0.10 | 0.0% | = MET |
Q1 2024 | Feb 29, 2024 | $0.11 | $0.09 | -18.2% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $0.11 | $0.11 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $0.13 | $0.12 | -7.7% | ✗ MISS |
Q2 2023 | May 8, 2023 | $0.12 | $0.12 | 0.0% | = MET |
Q1 2023 | Mar 1, 2023 | $0.14 | $0.16 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.11 | $0.10 | -9.1% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $0.11 | $0.09 | -18.2% | ✗ MISS |
Q2 2022 | May 5, 2022 | $0.11 | $0.11 | 0.0% | = MET |
Q1 2022 | Mar 1, 2022 | $0.09 | $0.01 | -88.9% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.06 | $0.07 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.05 | $0.03 | -40.0% | ✗ MISS |
Q2 2021 | May 6, 2021 | $0.04 | $0.06 | +34.8% | ✓ BEAT |
Latest News
Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $12
➖ NeutralBarclays Maintains Overweight on Certara, Lowers Price Target to $13
➖ NeutralStephens & Co. Maintains Overweight on Certara, Lowers Price Target to $12
➖ NeutralCertara Names Jon Resnick as CEO, William Feehery to Transition to Advisor, Reaffirms 2025 Outlook
📈 PositiveBMO Capital Initiates Coverage On Certara with Market Perform Rating, Announces Price Target of $9
➖ NeutralBarclays Maintains Overweight on Certara, Lowers Price Target to $14
➖ NeutralCertara Raises FY2025 Adj EPS Guidance from $0.42-$0.46 to $0.45-$0.47 vs $0.44 Est; Narrows FY2025 Sales Guidance from $415.000M-$425.000M to $415.000M-$420.000M vs $421.766M Est
📈 PositiveCertara Q3 Adj. EPS $0.14 Beats $0.11 Estimate, Sales $104.616M Miss $104.787M Estimate
📈 PositiveKeybanc Maintains Overweight on Certara, Raises Price Target to $16
📈 PositiveCraig-Hallum Initiates Coverage On Certara with Buy Rating, Announces Price Target of $16
📈 PositiveCertara expects Q1 sales above estimates
📈 PositiveFrequently Asked Questions about CERT
What is CERT's current stock price?
What is the analyst price target for CERT?
What sector is Certara, Inc. in?
What is CERT's market cap?
Does CERT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CERT for comparison